Biopharmaceutical company ADMA Biologics Inc. (ADMA) is steadily reinforcing its growth outlook, with reaffirmed multi-year financial targets and operational catalysts that continue to shape its trajectory.
For fiscal years 2025 and 2026, ADMA has reaffirmed its expectations for total revenue to exceed $500 million and $625 million, respectively, with adjusted net income projected to surpass $175 million in 2025 and $245 million in 2026.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.